These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26267600)

  • 1. A prospective randomized controlled trial assessing the efficacy of adjunctive hyperbaric oxygen therapy in the treatment of hidradenitis suppurativa.
    Yildiz H; Senol L; Ercan E; Bilgili ME; Karabudak Abuaf O
    Int J Dermatol; 2016 Feb; 55(2):232-7. PubMed ID: 26267600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation.
    Caposiena Caro RD; Molinelli E; Brisigotti V; Offidani A; Bianchi L
    Clin Exp Dermatol; 2021 Jan; 46(1):96-102. PubMed ID: 32683727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
    Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
    J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab versus Rifampicin Plus Clindamycin for the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Retrospective Study.
    Marasca C; Annunziata MC; Villani A; Volpe S; Marasca D; Fabbrocini G
    J Drugs Dermatol; 2019 May; 18(5):437-438. PubMed ID: 31141853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa.
    Mendonça CO; Griffiths CE
    Br J Dermatol; 2006 May; 154(5):977-8. PubMed ID: 16634904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up.
    Dessinioti C; Zisimou C; Tzanetakou V; Stratigos A; Antoniou C
    Clin Exp Dermatol; 2016 Dec; 41(8):852-857. PubMed ID: 27753139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.
    Amano M; Grant A; Kerdel FA
    Int J Dermatol; 2010 Aug; 49(8):950-5. PubMed ID: 21128923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
    J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Results from Period A of RELIEVE, a Multicenter Randomized, Controlled Trial.
    Schultheis M; Staubach P; Nikolakis G; Grabbe S; Ruckes C; von Stebut E; Kirschner U; Matusiak Ł; Szepietowski JC
    Dermatology; 2022; 238(3):476-486. PubMed ID: 34535610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa.
    Rosi E; Pescitelli L; Ricceri F; Di Cesare A; Novelli A; Pimpinelli N; Prignano F
    Dermatol Ther; 2019 Mar; 32(2):e12792. PubMed ID: 30515931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients.
    Gener G; Canoui-Poitrine F; Revuz JE; Faye O; Poli F; Gabison G; Pouget F; Viallette C; Wolkenstein P; Bastuji-Garin S
    Dermatology; 2009; 219(2):148-54. PubMed ID: 19590173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.
    Sotiriou E; Goussi C; Lallas A; Chovarda E; Apalla Z; Lazaridou E; Ioannides D
    J Drugs Dermatol; 2012 May; 11(5 Suppl):s15-20. PubMed ID: 22644772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study.
    Kerdel FR; Azevedo FA; Kerdel Don C; Don FA; Fabbrocini G; Kerdel FA
    J Drugs Dermatol; 2019 Feb; 18(2):170-176. PubMed ID: 30811140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system.
    Scheinfeld N
    Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of medical and surgical treatments for hidradenitis suppurativa using real-life data from the Scandinavian registry (HISREG).
    Grimstad Ø; Tzellos T; Dufour DN; Bremnes Ø; Skoie IM; Snekvik I; Jarnaess E; Kyrgidis A; Ingvarsson G
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1164-1171. PubMed ID: 30451320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS).
    Hessam S; Sand M; Gambichler T; Bechara FG
    J Am Acad Dermatol; 2015 Dec; 73(6):998-1005. PubMed ID: 26410359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin-clindamycin combination.
    Join-Lambert O; Ribadeau-Dumas F; Jullien V; Kitzis MD; Jais JP; Coignard-Biehler H; Guet-Revillet H; Consigny PH; Delage M; Nassif X; Lortholary O; Nassif A
    Eur J Dermatol; 2014; 24(1):94-5. PubMed ID: 24445967
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum amyloid A and C-reactive protein levels and erythrocyte sedimentation rate are important indicators in hidradenitis suppurativa.
    Akdogan N; Dogan S; Incel-Uysal P; Karabulut E; Topcuoglu C; Yalcin B; Atakan N
    Arch Dermatol Res; 2020 May; 312(4):255-262. PubMed ID: 31729595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa.
    Chiricozzi A; Faleri S; Franceschini C; Caro RD; Chimenti S; Bianchi L
    Wounds; 2015 Oct; 27(10):258-64. PubMed ID: 26479209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
    Miller I; Lynggaard CD; Lophaven S; Zachariae C; Dufour DN; Jemec GB
    Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.